BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Find People
Find Everything
About This Site
Edit My Profile
Login to Profiles
DIRECT2Experts
Help / FAQ

Announcement

You can now add alternative names! Click here to add other names that you've published under.

BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study.

Lesnock JL, Darcy KM, Tian C, Deloia JA, Thrall MM, Zahn C, Armstrong DK, Birrer MJ, Krivak TC. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Br J Cancer. 2013 Apr 02; 108(6):1231-7.

View in: PubMed

subject areas

Adenocarcinoma, Clear Cell
Adenocarcinoma, Mucinous
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
BRCA1 Protein
Cisplatin
Cystadenocarcinoma, Serous
Endometrial Neoplasms
Female
Follow-Up Studies
Humans
Immunoenzyme Techniques
Injections, Intraperitoneal
Middle Aged
Neoplasm Staging
Ovarian Neoplasms
Paclitaxel
Prognosis
Survival Rate

authors with profiles

Michael Birrer